- Home
- RVPH vs ARMP Comparison
RVPH vs ARMP Comparison
Compare RVPH & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPH
- ARMP
- Stock Information
- Founded
- RVPH 2006
- ARMP N/A
- Country
- RVPH United States
- ARMP United States
- Employees
- RVPH N/A
- ARMP N/A
- Industry
- RVPH Biotechnology: Pharmaceutical Preparations
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RVPH Health Care
- ARMP Health Care
- Exchange
- RVPH Nasdaq
- ARMP Nasdaq
- Market Cap
- RVPH 88.0M
- ARMP 80.0M
- IPO Year
- RVPH N/A
- ARMP N/A
- Fundamental
- Price
- RVPH $1.80
- ARMP $1.95
- Analyst Decision
- RVPH Strong Buy
- ARMP Strong Buy
- Analyst Count
- RVPH 5
- ARMP 1
- Target Price
- RVPH $11.40
- ARMP $7.00
- AVG Volume (30 Days)
- RVPH 1.6M
- ARMP 8.0K
- Earning Date
- RVPH 11-14-2024
- ARMP 03-20-2025
- Dividend Yield
- RVPH N/A
- ARMP N/A
- EPS Growth
- RVPH N/A
- ARMP N/A
- EPS
- RVPH N/A
- ARMP N/A
- Revenue
- RVPH N/A
- ARMP $5,467,000.00
- Revenue This Year
- RVPH N/A
- ARMP $23.87
- Revenue Next Year
- RVPH N/A
- ARMP N/A
- P/E Ratio
- RVPH N/A
- ARMP N/A
- Revenue Growth
- RVPH N/A
- ARMP 34.92
- 52 Week Low
- RVPH $0.60
- ARMP $1.80
- 52 Week High
- RVPH $4.50
- ARMP $4.48
- Technical
- Relative Strength Index (RSI)
- RVPH 45.36
- ARMP 42.06
- Support Level
- RVPH $1.97
- ARMP $1.89
- Resistance Level
- RVPH $2.14
- ARMP $2.08
- Average True Range (ATR)
- RVPH 0.16
- ARMP 0.10
- MACD
- RVPH -0.02
- ARMP -0.01
- Stochastic Oscillator
- RVPH 29.29
- ARMP 18.18
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.